Anti-osteoporotic medications: Traditional and nontraditional

被引：4

作者：

Cohen, DP ^{[1
]}

机构：

[1] Univ Chicago, Dept Obstet & Gynecol, Chicago, IL 60637 USA

来源：

CLINICAL OBSTETRICS AND GYNECOLOGY | 2003年 / 46卷 / 02期

关键词：

D O I：

10.1097/00003081-200306000-00012

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

[No abstract available]

引用

页码：341 / 348

页数：8

共 32 条

[1] Alendronate and estrogen effects in postmenopausal women with low bone mineral density [J].

Bone, HG ;

Greenspan, SL ;

McKeever, C ;

Bell, N ;

Davidson, M ;

Downs, RW ;

Emkey, R ;

Meunier, PJ ;

Miller, SS ;

Mulloy, AL ;

Recker, RR ;

Weiss, SR ;

Heyden, N ;

Musliner, T ;

Suryawanshi, S ;

Yates, AJ ;

Lombardi, A .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (02) :720-726

[2] Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: Four-year results from a randomized clinical trial [J].

Delmas, PD ;

Ensrud, KE ;

Adachi, JD ;

Harper, KD ;

Sarkar, S ;

Gennari, C ;

Reginster, JY ;

Pols, HAP ;

Recker, RR ;

Harris, ST ;

Wu, WT ;

Genant, HK ;

Black, DM ;

Eastell, R .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (08) :3609-3617

[3] Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women [J].

Downs, RW ;

Bell, NH ;

Ettinger, MP ;

Walsh, BW ;

Favus, MJ ;

Mako, B ;

Wang, LX ;

Smith, ME ;

Gormley, GJ ;

Melton, ME .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (05) :1783-1788

[4] Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene -: Results from a 3-year randomized clinical trial [J].

Ettinger, B ;

Black, DM ;

Mitlak, BH ;

Knickerbocker, RK ;

Nickelsen, T ;

Genant, HK ;

Christiansen, C ;

Delmas, PD ;

Zanchetta, JR ;

Stakkestad, J ;

Glüer, CC ;

Krueger, K ;

Cohen, FJ ;

Eckert, S ;

Ensrud, KE ;

Avioli, LV ;

Lips, P ;

Cummings, SR .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (07) :637-645

[5] Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss [J].

Gallagher, JC ;

Fowler, SE ;

Detter, JR ;

Sherman, SS .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (08) :3618-3628

[6] Effect of postmenopausal hormone therapy on cognitive function: The heart and estrogen/progestin replacement study [J].

Grady, D ;

Yaffe, K ;

Kristof, M ;

Lin, F ;

Richards, C ;

Barrett-Connor, E .

AMERICAN JOURNAL OF MEDICINE, 2002, 113 (07) :543-548

[7] Tolerability of once-weekly alendronate in patients with osteoporosis: A randomized, double-blind, placebo-controlled study [J].

Greenspan, S ;

Field-Munves, E ;

Tonino, R ;

Smith, M ;

Petruschke, R ;

Wang, LX ;

Yates, J ;

de Papp, AE ;

Palmisano, J .

MAYO CLINIC PROCEEDINGS, 2002, 77 (10) :1044-1052

[8] Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis - A randomized, double-blind, placebo-controlled trial [J].

Greenspan, SL ;

Emkey, RD ;

Bone, HG ;

Weiss, SR ;

Bell, NH ;

Downs, RW ;

McKeever, C ;

Miller, SS ;

Davidson, M ;

Bolognese, MA ;

Mulloy, AL ;

Heyden, N ;

Wu, M ;

Kaur, A ;

Lombardi, A .

ANNALS OF INTERNAL MEDICINE, 2002, 137 (11) :875-883

[9]

Hidaka S, 1999, PHYTOTHER RES, V13, P14, DOI 10.1002/(SICI)1099-1573(199902)13:1&lt

[10]

14::AID-PTR375&gt

← 1 2 3 4 →